Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.

Saved in:
Bibliographic Details
Title: Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
Authors: Meng B; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK., Abdullahi A; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK., Ferreira IATM; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK., Goonawardane N; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK., Saito A; Department of Veterinary Science, Faculty of Agriculture, University of Miyazaki, Miyazaki, Japan., Kimura I; Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Yamasoba D; Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Gerber PP; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK., Fatihi S; CSIR Institute of Genomics and Integrative Biology, Delhi, India., Rathore S; CSIR Institute of Genomics and Integrative Biology, Delhi, India., Zepeda SK; Department of Biochemistry, University of Washington, Seattle, WA, USA., Papa G; MRC-Laboratory of Molecular Biology, Cambridge, UK., Kemp SA; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK., Ikeda T; Division of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan., Toyoda M; Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan., Tan TS; Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan., Kuramochi J; Kuramochi Clinic Interpark, Utsunomiya, Japan., Mitsunaga S; Human Genetics Laboratory, National Institute of Genetics, Mishima, Japan., Ueno T; Division of Infection and Immunity, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan., Shirakawa K; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Takaori-Kondo A; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Brevini T; Department of Medicine, University of Cambridge, Cambridge, UK., Mallery DL; MRC-Laboratory of Molecular Biology, Cambridge, UK., Charles OJ; Division of Infection and Immunity, UCL, London, UK., Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA, USA., Joshi A; Department of Biochemistry, University of Washington, Seattle, WA, USA., Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Department of Virology, University of Cambridge, Cambridge, UK., Jackson L; Africa Health Research Institute, Durban, South Africa., Martin D; University of Cape Town, Cape Town, South Africa., Smith KGC; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK., Bradley J; Department of Medicine, University of Cambridge, Cambridge, UK., Briggs JAG; Max Planck Institute of Biochemistry, Martinsried, Germany., Choi J; Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK., Madissoon E; Welcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.; European Molecular Biology Laboratory, European Bioinformatics Institute, EMBL-EBI, Wellcome Trust Genome Campus, Hinxton, UK., Meyer KB; Welcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK., Mlcochova P; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK., Ceron-Gutierrez L; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK., Doffinger R; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK., Teichmann SA; Welcome Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.; Cavendish Laboratory, Department of Physics, University of Cambridge, Cambridge, UK., Fisher AJ; Transplant and Regenerative Medicine Laboratory, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK., Pizzuto MS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland., de Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland., Hosmillo M; Department of Virology, University of Cambridge, Cambridge, UK., Lee JH; Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK.; Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge, UK., James LC; MRC-Laboratory of Molecular Biology, Cambridge, UK., Thukral L; CSIR Institute of Genomics and Integrative Biology, Delhi, India., Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, Seattle, WA, USA., Sigal A; Africa Health Research Institute, Durban, South Africa.; Max Planck Institute for Infection Biology, Berlin, Germany.; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa., Sampaziotis F; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK., Goodfellow IG; Department of Virology, University of Cambridge, Cambridge, UK., Matheson NJ; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, UK.; NHS Blood and Transplant, Cambridge, UK., Sato K; Division of Systems Virology, Department of Infectious Disease Control, International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. keisato@g.ecc.u-tokyo.ac.jp.; CREST, Japan Science and Technology Agency, Saitama, Japan. keisato@g.ecc.u-tokyo.ac.jp., Gupta RK; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK. rkg20@cam.ac.uk.; Department of Medicine, University of Cambridge, Cambridge, UK. rkg20@cam.ac.uk.; Africa Health Research Institute, Durban, South Africa. rkg20@cam.ac.uk.
Corporate Authors: CITIID-NIHR BioResource COVID-19 Collaboration, Genotype to Phenotype Japan (G2P-Japan) Consortium, Ecuador-COVID19 Consortium
Source: Nature [Nature] 2022 Mar; Vol. 603 (7902), pp. 706-714. Date of Electronic Publication: 2022 Feb 01.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-4687
DOI:10.1038/s41586-022-04474-x